Bellecapital’s Denali Therapeutics DNLI Stock Holding History

Bellecapital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,644	Closed	-$600K	–	196
2021 Q2	$600K	Hold	7,644	–	–	0.18%	101
2021 Q1	$436K	Hold	7,644	–	–	0.14%	119
2020 Q4	$640K	Sell	7,644 -4,165	-35%	-$252K	0.21%	84
2020 Q3	$423K	Buy	+11,809	New	+$356K	0.19%	96

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellecapital's DNLI Position: Q3 2021 in Review

Bellecapital sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 7,644 shares — an estimated $600K sold.

Bellecapital first reported a position in DNLI in Q3 2020 and held it in 4 quarters. The position peaked at $640K in Q4 2020. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

Bellecapital reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
Bellecapital sold 7,644 Denali Therapeutics shares in Q3 2021, an estimated $600K.
Bellecapital first reported a position in Denali Therapeutics in Q3 2020 and held it in 4 quarters.
Bellecapital's Denali Therapeutics position peaked at $640K in Q4 2020.
214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Bellecapital's 13F filing for Q3 2021, filed 21 Oct 2021.